It is hypothesized that this resistance to T-DM1 was overcome by mechanisms including the bystander effect, which was mediated by the aforementioned properties of T-DXd, allowing the drug to penetrate cells adjacent to tumor-expressing target cells that have evolved resistance through decreased HER2 expression [12,23]. Here, ERBB2 is linked to neoplasm.